☰
Companies
▾
Companies
Calendar
Valuation
Screener
▾
Screener
Sectors
Magic Formula
Bubble Plot
Treemap
Chart Builder
Analysis
▾
Margins
Dividends
Buybacks
Insider Buying
CEO Changes
M&A Tracker
IPO Tracker
Short Selling
Markets
▾
Countries
US vs EU P/E
Fear & Greed
AI Models
AI Capex
Credit & Rates
▾
EU Yield Curve
US Yield Curve
US Federal Debt
Leverage
Repo Market
Mortgage Delinquency
Private Credit
Health
▾
Top Drugs
Diabetes
Immunology
Portfolio
▾
Portfolio
Berkshire
Buffett
Fund X-Ray
More
▾
Denmark
Danish Tax
Tesla
EU XBRL Tables
Contact
Obesity
Blog
2021Q3
1 post
Novo Nordisk 2021Q3 - Wegovy® bottlenecks
13 November 2021
·
2021Q3
Denmark
Diabetes
Novo Nordisk continues to succeed in the GLP-1 space with semaglutide ( Ozempic ®, Rybelsus ® and Wegovy ®).